Venaxis, Inc. (APPY)
-NasdaqCM 1.31 
0.05(3.68%) 2:29PM EDT - Nasdaq Real Time Price
| Prev Close: | 1.36 |
|---|
| Open: | 1.28 |
|---|
| Bid: | 1.31 x 34300 |
|---|
| Ask: | 1.32 x 42400 |
|---|
| 1y Target Est: | 6.50 |
|---|
| Beta: | 0.67 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 1.28 - 1.32 |
|---|
| 52wk Range: | 1.18 - 3.96 |
|---|
| Volume: | 10,662,648 |
|---|
| Avg Vol (3m): | 124,505 |
|---|
| Market Cap: | 13.04M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.42 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- BRIEF-Venaxis prices 10 million shares at $1.25 per shareat Reuters(Fri 10:34AM EDT)
- InPlay: Venaxis prices 10 mln shares and related warrants to purchase 3.5 mln shares (at 1.36) at a combined offering price of $1.25 per shareBriefing.com(Fri 1:32AM EDT)
- VENAXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements andEDGAR Online(Thu, May 23)
- Venaxis Announces Pricing of Offering of Common Stock and WarrantsPR Newswire(Thu, May 23)
- VENAXIS, INC. FinancialsEDGAR Online Financials(Tue, May 14)
- VENAXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial ObligatiEDGAR Online(Thu, May 9)
- VENAXIS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, May 7)
- Venaxis Poised For Run-Up Into Pivotal Study Resultsat Seeking Alpha(Sun, Apr 28)
- Venaxis Appoints SomaLogic CMO and former Pfizer Executive Stephen A. Williams, M.D., Ph.D., to Board of DirectorsPR Newswire(Thu, Apr 18)
- VENAXIS, INC. Files SEC form 8-K, Financial Statements and ExhibitsEDGAR Online(Thu, Apr 18)
- VENAXIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Tue, Apr 2)
- Venaxis Management Discusses Q4 2012 Results - Earnings Call Transcriptat Seeking Alpha(Tue, Mar 26)
- Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis TestPR Newswire(Tue, Mar 26)
- Pivotal Phase III Trial Data Ahead For 3 Development-Stage Small Pharma Companiesat Seeking Alpha(Tue, Mar 26)
- VENAXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, Mar 26)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 394.90 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.10 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.33 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | -0.11 |
|---|
Business Summary
Venaxis, Inc. develops and commercializes products for unmet diagnostic and therapeutic needs. The companys research and development activities primarily focus on a human acute appendicitis blood-based test.
View More